Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
Gavin Giovannoni, Joela Mathews
Neurology and Therapy (2022) Vol. 11, Iss. 2, pp. 571-595
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Heinz Wiendl, Frederik Barkhof, Xavier Montalbán, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis
Mar Barrantes-Cepas, Samantha Noteboom, Elisa Colato, et al.
Multiple Sclerosis Journal (2025)
Closed Access
Cladribine Is Associated With Stable Cortical Gray Matter Lesion Burden in Multiple Sclerosis: A 7T MRI Study
Jonathan Zurawski, Shahamat Tauhid, Brian C. Healy, et al.
Journal of Neuroimaging (2025) Vol. 35, Iss. 2
Closed Access
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence
Celia Oreja‐Guevara, Wallace Brownlee, Elisabeth Gulowsen Celius, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 69, pp. 104459-104459
Open Access | Times Cited: 23
Knowledge mapping of disease-modifying therapy (DMT) in multiple sclerosis (MS): A bibliometrics analysis
Fan Jiang, Fenghe Zhang, Yue Su, et al.
Heliyon (2024) Vol. 10, Iss. 11, pp. e31744-e31744
Open Access | Times Cited: 4
Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia
Seraj Makkawi, Ahmad Abulaban, Yaser Al Malik, et al.
Neurology and Therapy (2025)
Open Access
Identifying Cladribine prescription pattern in MS: an Italian multicentre study
Aurora Zanghì, Roberta Fantozzi, Matteo Foschi, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Real World Experience with Cladribine Tablets for Multiple Sclerosis at Four Academic Multiple Sclerosis Centers
Devon Conway, Jacqueline A. Nicholas, Nicolas R. Thompson, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 94, pp. 106272-106272
Closed Access
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
Sven G. Meuth, Antonios Bayas, Boris Kallmann, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 13, pp. 1503-1510
Open Access | Times Cited: 19
Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis
Rosa Cortese, Giovanna Testa, Francesco Assogna, et al.
CNS Drugs (2024) Vol. 38, Iss. 4, pp. 267-279
Open Access | Times Cited: 3
Summary of safety and efficacy of COVID-19 vaccination in patients with multiple sclerosis
Eva Pernicová, Petra Macounová, Martin Krsek, et al.
European Neurology (2023) Vol. 86, Iss. 4, pp. 263-276
Open Access | Times Cited: 9
Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
Gilles Edan, Emmanuelle Le Page
Drugs (2023) Vol. 83, Iss. 15, pp. 1351-1363
Open Access | Times Cited: 8
Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4
David Magalashvili, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Journal of Neuroimmunology (2022) Vol. 372, pp. 577966-577966
Closed Access | Times Cited: 12
Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers
Mario Habek, Jelena Drulović, Gregor Brecl Jakob, et al.
Neurology and Therapy (2022) Vol. 12, Iss. 1, pp. 25-37
Open Access | Times Cited: 12
S1PR1 modulators in multiple sclerosis: Efficacy, safety, comparison, and chemical structure insights
Omid Jamshidi Kandjani, Shadi Yaqoubi, Samad Shams Vahdati, et al.
European Journal of Medicinal Chemistry (2023) Vol. 250, pp. 115182-115182
Closed Access | Times Cited: 7
Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple Sclerosis
de Sèze, Dominique Dive, Xavier Ayrignac, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 3, pp. 519-533
Open Access | Times Cited: 2
Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model
Ide Smets, Matthijs Versteegh, Simone Huygens, et al.
Multiple Sclerosis Journal (2024) Vol. 30, Iss. 8, pp. 1016-1025
Open Access | Times Cited: 2
Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
Diego Centonze, Maria Pia Amato, Vincenzo Brescia Morra, et al.
Therapeutic Advances in Neurological Disorders (2023) Vol. 16
Open Access | Times Cited: 6
Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis
Michael Hecker, Niklas Frahm, Uwe K. Zettl
Pharmaceutics (2023) Vol. 16, Iss. 1, pp. 3-3
Open Access | Times Cited: 5
Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study
Jihad Inshasi, Samar Farouk, Ahmed Shatila, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 4, pp. 1309-1318
Open Access | Times Cited: 5
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus
de Sèze, Laurent Suchet, Claude Mékiès, et al.
Neurology and Therapy (2022) Vol. 12, Iss. 2, pp. 351-369
Open Access | Times Cited: 8
Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic
Adam Stępień, Aleksandra Pogoda-Wesołowska, E Tokarz-Kupczyk, et al.
Neurologia i Neurochirurgia Polska (2023) Vol. 57, Iss. 4, pp. 371-378
Open Access | Times Cited: 4
Bioavailable central nervous system disease-modifying therapies for multiple sclerosis
Hans‐Peter Hartung, Bruce Cree, Michael Barnett, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers
Ivan Adamec, Gregor Brecl Jakob, Cecília Rajda, et al.
Journal of Neuroimmunology (2023) Vol. 382, pp. 578164-578164
Open Access | Times Cited: 3
RETRACTED: Cladribine induces apoptosis, neuroinflammation, mitochondrial oxidative stress, tau phosphorylation and Aβ (1−42) pathway in the hippocampus: An in vivo approach
Khadga Raj Aran, Ghanshyam Das Gupta, Shamsher Singh
Journal of Chemical Neuroanatomy (2023) Vol. 133, pp. 102340-102340
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top